Canaccord analyst William Plovanic lowered the firm’s price target on iRhythm (IRTC) to $139 from $152 and keeps a Buy rating on the shares. The firm beat estimates and on the regulatory front, the company reiterated its expectation to submit Zio Monitor in 3Q while the company is also on track to complete the additional compliance efforts related to the Warning Letter and 483 observations by year-end 2025.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRTC:
- Irhythm Technologies: Strong Q1 2025 Performance and Raised Price Target Reinforce Buy Rating
- Strong Commercial Momentum and Strategic Partnerships Drive Buy Rating for Irhythm Technologies
- Wells upgrades iRhythm to Overweight on strong business trends
- iRhythm upgraded to Overweight from Equal Weight at Wells Fargo
- iRhythm Technologies Reports Strong Q1 2025 Growth